Jefferson University Hospitals

Provider Profile

Adam P. Dicker, MD, PhD, FASTRO

Jefferson University Physician

Academic Title: Professor
Sr. VP and Chair, Enterprise Radiation Oncology
Professor of Radiation Oncology, Pharmacology & Experimental Therapeutics

Radiation Oncology
Radiation Oncology - Bladder Cancer
Radiation Oncology - Brain Tumor
Radiation Oncology - Kidney Cancer
Radiation Oncology - Prostate Cancer
Radiation Oncology - Testicular Cancer
Radiation Oncology - Uveal Melanoma

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Bodine Center, Suite G-301
111 South 11th Street
Philadelphia PA 19107
Phone: (215) 955-6702
Fax: (215) 955-0412

Medical Services

Years in Practice


Board Certifications

  • Radiation Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012,2011,2010

Personal Statement

I provide personalized medicine using the latest developments in individualized genomic health. Each patient is treated as a family member.


  • Cornell University Medical College, Medical School


  • Lenox Hill Hospital, NY


  • Memorial Sloan-Kettering Cancer Center


  • Memorial Sloan-Kettering Cancer Center

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • AmeriHealth
  • Amerihealth 65
  • Amerihealth Caritas
  • AmeriHealth HMO
  • AmeriHealth Personal Choice
  • BC BS Special Care
  • Blue Cross/Blue Shield
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Coventry/Health America
  • Devon
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • First Health Network
  • Fortified Provider Network
  • Galaxy
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • Horizon HMO
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Intergroup Preferred
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone First/Connect
  • Keystone Health Plan East
  • Medicaid of PA
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Blue Shield
  • One Net PPO
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • PPO Next
  • Preferred Care PPO
  • Prime Health Services, Inc.
  • Private Healthcare Systems (PHCS)
  • Provider Select Inc
  • Qualcare
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan

Recent Publications

Common error pathways seen in the RO-ILS data that demonstrate opportunities for improving treatment safety

Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer

Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704

Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program

Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017

Blockade of Tumor-Expressed PD-1 promotes lung cancer growth

Ensuring sample quality for blood biomarker studies in clinical trials: A multicenter international study for plasma and serum sample preparation

Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer the NRG oncology rtog 0436 phase 3 randomized clinical trial

Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non–Small Cell Lung Cancer: NRG Oncology RTOG 0839

Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases

Increasing faculty participation in resident education and providing cost-effective self-assessment module credit to faculty through resident-generated didactics

IGFBP3 modulates lung tumorigenesis and cell growth through IGF1 signaling

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)

Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model

Individual patient-level meta-Analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease

Comparison of Online 6 Degree-of-Freedom Image Registration of Varian TrueBeam Cone-Beam CT and BrainLab ExacTrac X-Ray for Intracranial Radiosurgery

Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer

The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31stanniversary annual meeting